Organovo Holdings, Inc. (ONVO)

[RandolRocketman]

Organovo’s 3D bioprinted human liver tissues function for at least four weeks and are comprised of a complex multicellular architecture that more closely emulates human biology and disease. The Company’s tissue systems have the potential to facilitate breakthrough translational research from target discovery to high-value drug profiling, enabling better understanding of disease processes, discovery of novel therapeutics, biomarkers, and the safety assessment of drugs in a disease-relevant background.

Organovo to Present at 2nd Annual NASH Summit
BY GlobeNewswire
— 8:05 AM ET 04/24/2018

Event: 2nd Annual NASH Summit
Presentation Title: Modeling NAFLD/NASH In Vitro Using 3D Bioprinted Human Liver Tissue
Date & Time: Thursday, April 24th at 4:00pm ET
Location: Revere Hotel Boston Common, Boston, Ma.